

Original Article

Are high urea values before intravenous immunoglobulin replacement a risk factor for COVID-related mortality?

Running Title: Risk factors for COVID-related mortality?

Gökhan AYTEKİN^{1,*}, Emel ATAYIK¹

¹Department of Immunology and Allergy, Konya City Hospital, Konya, Turkey

***Correspondence:** ayteking@gmail.com

ORCIDs:

Gökhan AYTEKİN: <https://orcid.org/0000-0002-9089-5914>

Emel ATAYIK: <https://orcid.org/0000-0002-7011-7752>

Corresponding Author:

Gokhan AYTEKIN, MD,
University of Health Sciences, Konya City Hospital,
Division of Allergy and Clinical Immunology,
42080, Konya Turkey
Phone: +90 505 533 73 55 **Email:** ayteking@gmail.com

27

28 **Informed consent**

29 The study protocol was approved by the Ethics committee of the Karatay University
30 (with the decision dated 09.02.2021, decision number: 2020/021). Informed consent
31 was obtained from study participants.

32 Manuscripts that have not been presented orally or as a poster.

33 **Funding source:** No funding was secured for the study.

34 **Financial disclosure:** The authors have no financial relationship relevant to this article
35 to disclose.

36 **Conflict of interest:** The authors have no conflicts of interest to disclose.

37 **Acknowledgement:** None

38 **Disclaimers:** None

39 **Abstract word count:** 250

40 **Text word count:** 3097

41

42

43

44

45

46

47

48

49

50 ORIGINAL ARTICLE

51 **Title of the manuscript:** Are high urea values before intravenous immunoglobulin
52 replacement a risk factor for COVID-related mortality?

53 Abstract

54 **Objective:** Since the World Health Organization accepted The Coronavirus Disease
55 2019 (COVID-19) as a pandemic and there is still no effective treatment, it becomes
56 crucial that the physicians interested in COVID-19 treatment share all the data they
57 acquire, particularly in vulnerable patient groups, to reduce morbidity and mortality.

58 **Methods:** The study included 81 adult (Female: 27, Male: 54) COVID-19 patients who
59 were hospitalized for the treatment of COVID-19 between April 2020 and September
60 2020 and were followed-up, treated and consulted in the immunology clinic for
61 intravenous immunoglobulin (IVIG) treatment.

62 **Results:** The univariate analysis found that the number of days of hospitalization in
63 service, being intubated, number of IVIG treatment days, and the urea value before
64 IVIG treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074,
65 p:0.004, respectively). As a result of multivariate analysis, being intubated and urea
66 value before IVIG treatment were found to be independent risk factors for mortality
67 (p:0.001 and p:0.009).

68 It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity
69 value for mortality in COVID-19 patients was 46.2%, and the specificity was 35.5%
70 (p:0.029)

71 **Conclusion:** The study found that urea values before IVIG treatment were a risk factor
72 for mortality in patients who received IVIG treatment for COVID-19. This is important
73 as it indicates that BUN values should be closely monitored in patients given IVIG

74 treatment for COVID-19. It also suggests that when resources are limited and risk

75 stratification is required in COVID-19 patients, BUN values can be helpful.

76 **Keywords:** SARS-CoV-2, immunoglobulin, mortality, blood urea nitrogen, COVID-19

77 -

78

1. Introduction

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (Sars-CoV-2), has affected the whole world in economic, social, spiritual, and many other areas, particularly in the field of health, since December 2019, when it was first described (1, 2). As the disease is highly contagious, the virus spread worldwide in a short time and caused one of the most catastrophic pandemics in human history (3). Although there are some vaccines to reduce virus transmission and develop protection against it, it is obvious that vaccinating all the people in the world will not be possible in such short term. Although it has been more than one year since the WHO (World Health Organization) accepted COVID-19 as a pandemic, there is still no effective treatment. Until now, many treatment options, particularly antimalarial drugs and antivirals, systemic corticosteroids, tocilizumab, anakinra, conventional plasma therapy, and intravenous immunoglobulin (IVIG) therapy, have been tried in the form of monotherapy or combinations for treating COVID-19, there is still no consensus on its treatment (4-7).

For this reason, it becomes crucial that the physicians interested in COVID-19 treatment share all the data they acquire, particularly in vulnerable patient groups, to reduce morbidity and mortality. Regarding COVID-19 treatment management, many countries have created their treatment protocols, and many associations have published guidelines for its treatment. COVID-19 treatment in Turkey has been primarily applied in line with the TC Ministry of Health protocols. In general, the patients positive for SARS-CoV-2 Polymerase Chain Reaction (PCR) (+) were put on hydroxychloroquine and favipiravir treatment at appropriate doses. Patients who did not benefit from these treatments

103 and/or had underlying risk factors were hospitalized. In addition to respiratory support
104 treatments, patients were treated with conventional plasma, systemic steroid therapy,
105 immunomodulatory therapies such as tocilizumab and anakinra, and IVIG treatment,
106 whichever appropriate, as line therapies (8). IVIG was administered as per the clinical
107 immunologists' opinions and in the proper dose and time intervals.

108 Considering that pulmonary lesions in COVID-19 are caused by viral infiltrates and
109 inflammatory response, IVIG treatment provides inflammatory cytokine balance,
110 inhibits auto-reactive T cells, reduces antibody production from CD19⁺ B cells, and
111 reduces macrophage activity. The IVIG treatment is thought to provide a regression in
112 pulmonary lesions, reducing the need for mechanical ventilation, length of hospital stay,
113 and mortality rates in these patients (9, 10). Therefore, this study aimed to
114 retrospectively examine the data of patients who reported to the immunology clinic for
115 IVIG treatment in a tertiary referral hospital and who were hospitalized, followed up,
116 and treated for COVID-19. The study also investigated the effects of the patients'
117 clinical, laboratory, and treatment characteristics and risk factors for mortality in
118 patients with COVID-19 treating with IVIG treatment.

119 **2. Methods**

120 **Study design and study population**

121 The study included 81 adult (Female [F]: 27, 33.3%; Male [M]: 54, 66.7%) COVID-19
122 patients who were hospitalized for the treatment of COVID-19 in a tertiary referral
123 hospital between April 2020 and September 2020 and were followed-up, treated and
124 consulted in the immunology clinic for IVIG treatment. A review of medical records
125 (including information on age, sex, disease duration) was undertaken. Venous blood
126 samples for biochemical analyses were drawn after at least ten hours of fasting, early in

127 the morning. All biochemical analyses were conducted in the Central Biochemistry
128 Laboratory of the Konya Education and Research Hospital.

129 Complete blood counts were performed using Sysmex XN-10 (Sysmex Corporation,
130 Kobe, Japan) analyzers with the fluorescent flow cytometry method. Serum creatinine
131 levels were measured using the Jaffe method. Quantitative determination of serum IgG,
132 IgM, IgA, and IgE was done through particle-enhanced immunonephelometry using the
133 Siemens BN II/BN ProSpec system (Erlangen, Germany).

134 The follow-up period of all patients started with their hospitalization. For the patients
135 who died, the number of days between the date of hospitalization and death was
136 accepted as the follow-up period. The duration of follow-up was calculated by
137 confirming whether the discharged patients were alive or not through the TC Death
138 Reporting System 2 weeks after discharge. For patients who died within two weeks of
139 discharge, the follow-up period was accepted as the number of days between the date of
140 hospitalization and death. For patients who lived more than two weeks after discharge,
141 the follow-up period was calculated by adding 14 days to the number of days they
142 stayed in the hospital.

143 The time until hospitalization, resulting from the emergence of SARS-CoV-2-related
144 symptoms such as fever, cough, and body pain, was considered the duration of illness.

145 The duration of the follow-up in the service was specified as the day of hospitalization
146 and the follow-up period in the intensive care unit as the duration of intensive care
147 hospitalization. All patients in the study received IVIG treatment. Some patients were
148 followed only in the service and received IVIG treatment in the service. Some patients
149 received IVIG treatment in the intensive care unit. Patients who received IVIG

150 treatment in the service and those who received IVIG treatment in the first 24/48 h after
151 their admission to intensive care were specified as the IVIG treatment ICU first 24/48 h.

152 The systemic inflammatory index (SII) was calculated by the formula platelet x
153 neutrophil/lymphocyte. The SARS-CoV-2 diagnosis was established with the detection
154 of the SARS-CoV-2 genome via the PCR method from the nasopharyngeal sample
155 (nasal swab) in patients with symptoms suggestive of SARS-CoV-2 infection such as
156 fever, cough, shortness of breath, joint and body pain, and/or viral infiltration on lung
157 imaging (PA chest radiography or lung tomography).

158 The permission for the study was obtained from the Republic of Turkey, Ministry of
159 Health Scientific Research Platform. In addition, an ethics committee approval was
160 obtained from Karatay University Ethics Committee (with the decision dated
161 09.02.2021, decision number: 2020/021). Written informed consent was obtained from
162 each patient. The study was conducted as per the principles of the Declaration of
163 Helsinki.

164 **Statistical Analyses**

165 Statistical analyses were performed using the SPSS version 22.0 software package
166 (IBM Corp., Armonk, NY, USA). Normally distributed parameters were presented as
167 mean \pm standard deviation, and data that were not normally distributed were expressed
168 as median (interquartile range: minimum-maximum). Descriptive data were presented
169 as frequencies and percentages and compared using the Chi-square test. Comparisons
170 between baseline characteristics were performed by independent Student t, Mann-
171 Whitney rank-sum, Fisher's exact or Chi-square tests where appropriate. Independent
172 predictors for mortality were determined using binomial logistic regression analysis,
173 Cox regression analysis, and Kaplan-Meier test. ROC curves are used to choose the

174 most appropriate cut-off for urea level. A *p*-value of <0.05 was considered statistically
175 significant.

176

177 **3. Results**

178 A total of 81 patients, 27 of whom were women (33.3%), were included in the study.

179 The average age of the patients was 71 (26–94) years. During the follow-up, the

180 mortality rate was 64.2%. The rate of intubated patients was 45.7%. The average

181 follow-up period was 19 (1–38) days. The duration of hospitalization was 17 (1–38)

182 days, and the duration of hospitalization in intensive care was 10 (0–30) days. All

183 patients received hydroxychloroquine and favipiravir treatment during their follow-up.

184 In addition, IVIG treatment was given to all patients. While 35 patients (43.2%)

185 received tocilizumab treatment, 15 patients (18.5%) received conventional plasma and

186 33 patients (40.7%) received pulse steroid treatment. 61.7% of the patients in the first

187 24 h of their admission to intensive care, and 64.2% of the patients in the first 48 h of

188 their admission to intensive care received IVIG treatment. The demographic, laboratory,

189 and clinical characteristics of the patients have been summarized in Table 1.

190 There was no statistically significant difference between the patients who died during

191 their follow-up and the patients who survived in terms of age, gender, tocilizumab

192 treatment, conventional plasma treatment, and the number of days of hospitalization in

193 the service. We observed significant differences in terms of intubated patient ratio, pulse

194 steroid therapy, hospitalization white blood cell count, hospitalization platelet count,

195 lymphocyte percentage before IVIG treatment, neutrophil count before IVIG treatment,

196 hospitalization C-reactive protein (CRP) values, CRP levels before IVIG treatment, urea

197 values before IVIG treatment, hospitalization lactate dehydrogenase (LDH) levels,

hospitalization systemic inflammatory index (SII) levels, SII levels before IVIG treatment, and NLR (Neutrophil Lymphocyte Ratio) levels before IVIG treatment. The comparison of demographic, laboratory, and clinical characteristics of the patients who died and survived has been summarized in Table 1.

The univariate analysis found that the number of days of hospitalization in service, being intubated, number of IVIG treatment days, and the urea value before IVIG treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074, p:0.004, respectively) (Table 2). As a result of multivariate analysis, being intubated and urea value before IVIG treatment were found to be independent risk factors for mortality (p:0.001 and p:0.009, respectively) (Table 3).

It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity value for mortality in COVID-19 patients receiving IVIG treatment was 46.2%, and the specificity was 35.5% (p:0.029) (Table 4) (Figure 1).

4. Discussion

The SARS-CoV-2 virus has caused one of the most severe pandemics in human history and has put a lot of pressure, particularly on healthcare systems, since March 2020, when it was declared as a pandemic by WHO. The SARS-CoV-2 virus has caused the deaths of approximately 3 million people in nearly one year since its outbreak (2, 11). At present, there is no globally accepted treatment scheme for treating patients hospitalized for COVID-19. Therefore, it is crucial to determine the prognostic factors in vulnerable patient groups and to develop treatment modalities specific to patient groups according to these factors to reduce mortality and morbidity. In line with this opinion, this study found that being intubated and urea values before IVIG treatment are

independent risk factors for COVID-19-related mortality in patients hospitalized for COVID-19 and given IVIG treatment.

It has been reported that 7% of COVID-19 patients develop acute renal failure (12, 13). In addition, renal failure has been reported to increase COVID-19-related hospital deaths in mortality studies (14-19). Cheng et al. (15) showed an increase in blood urea nitrogen increased mortality 3.97 times in COVID-19 patients. Another study reported that hospitalization blood urea nitrogen (BUN) and D-dimer levels were associated with mortality, and BUN values of ≥ 4.6 mmol/L included a high risk for hospital deaths (14). In another study, 6.29% of COVID-19 patients showed an increase in BUN, and increased basal BUN and creatinine values were reported to cause high mortality (17). Ng et al. (18) reported that being intubated and BUN values are risks for hospital mortality in patients with end-stage renal disease and COVID-19. Although the increase in BUN after SARS-CoV-2 is frequent, the reason for this increase is not clear. Renal epithelial cells contain angiotensin-converting enzyme 2 (ACE2) receptors that are 100 times more intense than respiratory epithelial cells; SARS-CoV-2 is internalized to renal cells and may cause renal function loss with cytopathic effect (15, 20). It has been suggested that this may increase the absorption of BUN from the renal tubules by activating the renin-angiotensin-aldosterone system (20). Although IVIG treatment is often used as one of the last treatment options in patients who do not respond to other treatments, IVIG treatment itself may be associated with renal damage (13).

On the other hand, the increase in BUN levels in COVID-19 patients may be an indicator of kidney dysfunction and an increased inflammatory state. The renal load caused by increased catabolism, hypovolemia-induced renal hypoperfusion, sepsis, drugs used in the treatment of COVID-19 such as steroid therapy, and rhabdomyolysis

may also cause an increase in BUN. Although creatinine, another indicator of renal damage, was not found to be a predictor of mortality in this study, the fact that BUN is predictive of mortality suggests that BUN increases due to inflammatory conditions rather than a renal-induced reason and that increased inflammatory processes play a role in making BUN a risk factor for mortality. Another situation supporting this hypothesis is that inflammatory markers of the patients who died before IVIG treatment were prominently higher and statistically significant than the alive patients. As the most common cause of mortality in COVID-19 is a respiratory failure caused by cytokine storm, the majority of patients (81.5%) in the present study had to be followed up in the intensive care unit due to deterioration in their clinical condition. IVIG treatment is one of the last options in COVID-19 patients who are unresponsive to other therapies and whose cytokine storms are not controlled. It was thought that these patients face an intense inflammatory process, which causes an increase in BUN. The retrospective design, relatively small study population, lack of evaluation of other renal markers such as proteinuria and hematuria, and lack of knowledge of what happened in the post-follow-up period form the main limitations of this study.

5. Conclusion

In conclusion, the study found that urea values before IVIG treatment were a risk factor for mortality in patients who received IVIG treatment for COVID-19. This is important as it indicates that BUN values should be closely monitored in patients given IVIG treatment for COVID-19. It also suggests that when resources are limited and risk stratification is required in COVID-19 patients, BUN values can be helpful.

270

271

272 **References**

- 273 1. Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics,
274 therapy and vaccination. *Theranostics* 2020; 10(17): 7821-35. 2020/07/21. doi:
275 10.7150/thno.47987.
- 276 2. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a
277 global health crisis. *Physiol Genomics* 2020; 52(11): 549-57. 2020/09/30. doi:
278 10.1152/physiolgenomics.00089.2020.
- 279 3. Ferrer R. [COVID-19 Pandemic: the greatest challenge in the history of critical
280 care]. *Med Intensiva (Engl Ed)* 2020; 44(6): 323-4. 2020/05/08. doi:
281 10.1016/j.medin.2020.04.002.
- 282 4. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery,
283 diagnostics and drug development. *Journal of hepatology* 2021; 74(1): 168-84.
284 2020/10/11. doi: 10.1016/j.jhep.2020.09.031.
- 285 5. Echeverria-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio
286 Cusco M, Ferrandez O, Horcajada JP, et al. Azithromycin in the treatment of COVID-
287 19: a review. *Expert review of anti-infective therapy* 2021; 19(2): 147-63. 2020/08/28.
288 doi: 10.1080/14787210.2020.1813024.
- 289 6. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview.
290 *European journal of pharmacology* 2020; 889: 173644. 2020/10/15. doi:
291 10.1016/j.ejphar.2020.173644.
- 292 7. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2:
293 Structure, Biology, and Structure-Based Therapeutics Development. *Frontiers in*
294 *cellular and infection microbiology* 2020; 10: 587269. 2020/12/17. doi:
295 10.3389/fcimb.2020.587269.
- 296 8. Bakanlıgı TCS, Müdürlüğü HSG. COVID-19 rehberi antitoksin-anti inflammatua
297 rtedaviler koagulopati yönetimi. 2020, 7 November.
- 298 9. Mazeraud A, Goncalves B, Aegerter P, Mancusi L, Rieu C, Bozza F, et al. Effect
299 of early treatment with polyvalent immunoglobulin on acute respiratory distress
300 syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a
301 randomized controlled trial. *Trials* 2021; 22(1): 170. 2021/03/03. doi: 10.1186/s13063-
302 021-05118-7.
- 303 10. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular
304 intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with
305 COVID-19. *J Infect* 2020; 81(2): 318-56. 2020/04/14. doi: 10.1016/j.jinf.2020.03.044.
- 306 11. Worldometer. COVID-19 CORONAVIRUS PANDEMIC. 2021, March 28.
- 307 12. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute
308 kidney injury in patients hospitalized with COVID-19. *Kidney Int* 2020; 98(1): 209-18.
309 2020/05/18. doi: 10.1016/j.kint.2020.05.006.
- 310 13. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin:
311 adverse effects and safe administration. *Clin Rev Allergy Immunol* 2005; 29(3): 173-84.
312 2006/01/05. doi: 10.1385/CRIAI:29:3:173.

14. Cheng A, Hu L, Wang Y, Huang L, Zhao L, Zhang C, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. *International journal of antimicrobial agents* 2020; 56(3): 106110. 2020/07/28. doi: 10.1016/j.ijantimicag.2020.106110.
15. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; 97(5): 829-38. 2020/04/06. doi: 10.1016/j.kint.2020.03.005.
16. Liu Q, Wang Y, Zhao X, Wang L, Liu F, Wang T, et al. Diagnostic Performance of a Blood Urea Nitrogen to Creatinine Ratio-based Nomogram for Predicting In-hospital Mortality in COVID-19 Patients. *Risk management and healthcare policy* 2021; 14: 117-28. 2021/01/21. doi: 10.2147/rmhp.S278365.
17. Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney Function Indicators Predict Adverse Outcomes of COVID-19. *Med (New York, NY)* 2021; 2(1): 38-48.e2. 2020/10/13. doi: 10.1016/j.medj.2020.09.001.
18. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. *Kidney Int* 2020; 98(6): 1530-9. 2020/08/19. doi: 10.1016/j.kint.2020.07.030.
19. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: A systematic review and meta-analysis of 40 studies and 24,527 patients. *Pharmacological research* 2020; 161: 105107. 2020/08/03. doi: 10.1016/j.phrs.2020.105107.
20. Nogueira SAR, Oliveira SCS, Carvalho AFM, Neves JMC, Silva L, Silva Junior GBD, et al. Renal changes and acute kidney injury in covid-19: a systematic review. *Rev Assoc Med Bras (1992)* 2020; 66Suppl 2(Suppl 2): 112-7. 2020/09/24. doi: 10.1590/1806-9282.66.S2.112.

350

351 **Table 1:** Baseline demographic, clinical, and laboratory parameters of the study
352 population

Variable	Total (n: 81)	Dead (n:52)	Alive (n: 29)	p
Age	72 (41-94)	73.0 (41-94)	61 (46-78)	0.391
Gender, F, n (%)	27 (33.3)	17 (32.7)	10 (34.5)	0.870
Follow up time, day	19 (1-60)	20 (1-38)	16 (3-60)	0.745
Duration of illness, day	7 (3-10)	7 (3-10)	7 (3-8)	0.846
Day of stay in hospital	16 (1-44)	17 (1-38)	16 (3-44)	0.557
Day of stay in inpatient service	7.90 ±5.98	7.15 ±6.03	9.24 ±5.75	0.133
Day of stay in intensive care	10 (0-31)	9.5 (0-31)	13 (2-21)	0.509
Intensive care, n (%)	66 (81.5)	48 (92.3)	18 (62.1)	0.001
Intubation, n (%)	37 (45.7)	34 (65.2)	3 (10.3)	0.001
Comorbidity	60 (74.1)	40 (76.9)	20 (69.0)	0.433
Treatment properties				
Convalescent plasma, n (%)	15 (18.5)	9 (17.3)	6 (20.7)	0.707
Pulse steroid therapy, n (%)	33 (40.7)	28 (53.8)	5 (17.2)	0.001
Tocilizumab treatment, n (%)	35 (43.2)	19 (36.5)	16 (55.2)	0.105
IVIG treatment, at least	68 (84)	42 (80.8)	26 (89.7)	0.296

three days, n (%)				
IVIG treatment, in first 24 h, n, %	50 (61.7)	30 (57.7)	20 (69.0)	0.317
IVIG treatment, in first 48 h, n, %	52 (64.2)	32 (61.5)	20 (69.0)	0.504
Duration of IVIG treatment, day	3 (1-5)	3 (1-5)	3 (2-5)	0.069
IVIG dose, gr/day	40 (25-50)	40 (25-50)	50 (30-50)	0.832
Hematological parameters				
WBC count, on hospitalization	7,960 (1,176-27,350)	8,185 (1,176-27,350)	7,349.31 (2,630-20,110)	0.020
WBC count, before IVIG treatment	9,570 (430-27,290)	11,955 (430-27,290)	8,190 (1,220-25,920)	0.008
Neutrophil count, on hospitalization,	7,156.94 ±4,508.17	7,716.58 ±4,459.34	6,153 ±4,496.95	0.136
Neutrophil percentage, on hospitalization	84.50 (26.10-96.60)	85.50 (26.10-96.60)	78.10 (50.20-94.20)	0.100
Lymphocyte count, on hospitalization	770 (300-1,777)	690 (300-1,770)	780 (600-1,510)	0.512
Lymphocyte percentage, on hospitalization	11.30 (2.20-33.10)	9.30 (2.20-0)	12 (3-33.10)	0.081
Lymphocyte count, before IVIG treatment	520 (130-1,670)	460 (130-1,490)	730 (140-1,670)	0.294

Lymphocyte percentage, before IVIG treatment	4.30 (0.80-46.50)	3.35 (0.80-46.50)	5.60 (2.60-35.70)	0.001
Platelet count, $\times 10^3$, on hospitalization	192 (71-442)	204 (71-372)	191 (75-422)	0.030
Platelet count, $\times 10^3$, before IVIG treatment	244.19 \pm 112.82	240.92 \pm 122.01	250.04 \pm 95.88	0.730
Eosinophil count, on hospitalization	0 (0-130)	0 (0-130)	0 (0-80)	0.689
Eosinophil percentage, on hospitalization	0 (0-1.20)	0 (0-0.90)	0 (0-1.20)	0.994
Eosinophil count, before IVIG treatment	0 (0-180)	0 (0-180)	0 (0-120)	0.077
RDW, on hospitalization	12.40 \pm 2.58	12.32 \pm 2.61	12.55 \pm 2.56	0.706
RDW, before IVIG treatment	11.80 (8.40-20.40)	12.05 (9.40-20.40)	10.80 (8.40-17.70)	0.394
Biochemical Parameters				
Fasting blood glucose, mg/dL, on hospitalization	140 (75-480)	154 (84-361)	122 (75-480)	0.034
Fasting blood glucose, before IVIG treatment	165 (77-344)	180 (88-344)	123 (77-263)	0.195
Urea, on hospitalization	42 (15-256)	42.50 (15-256)	41 (17-180)	0.863

Urea, before IVIG treatment	59 (17-230)	60.50 (33-230)	43 (17-79.10)	0.029
Creatine, on hospitalization	1.03 (0.58-6.87)	1.04 (0.58-6.87)	1.02 (0.6-2.20)	0.629
Creatine, before IVIG treatment	0.8 (0.5-2.60)	0.9 (0.52-2.60)	0.80 (0.50-1.22)	0.544
LDH, on hospitalization	457 (188-4,367)	516 (190-4,367)	384 (188-1,015)	0.012
LDH, before IVIG treatment	570.81 ±213.58	597.10 ±201.48	524.59 ±229.67	0.145
D-dimer, on hospitalization	0.90 (0.20-5.70)	0.80 (0.20-5.70)	0.90 (0.30-2.10)	0.775
D-dimer, before IVIG treatment	4.59 ±7.59	4.93 ±7.98	3.87 ±6.93	0.549
Fibrinogen, on hospitalization	707.47 ±228.52	720.08 ±247.29	685.39 ±193.60	0.525
Fibrinogen, before IVIG treatment	635.22 ±279.67	636.81 ±278.53	632.81 ±286.64	0.950
Ferritin, on hospitalization	475.10 (43-4568)	550 (43-4,568)	114 (90.2-1,305)	0.389
Ferritin, before IVIG treatment	655 (83-3,345)	699 (83-3,345)	623 (114-1,659)	0.613
IgG, on hospitalization	8.36 ±4.04	9.64 ±2.70	7.08 ±4.87	0.188
IgM, on hospitalization	0.60 ±0.41	0.58 ±0.49	0.62 ±0.33	0.859

IgA, on hospitalization	2.52 (0.37-7.62)	2.56 (0.37-7.62)	2.42 (0.37-7.62)	0.198
Inflammatory Markers				
CRP, on hospitalization	91.2 (3-415)	124 (3-415)	53.70 (8.52-317)	0.015
CRP, before IVIG treatment	47.0 (3.10-297)	82.05 (3.10-297)	20.80 (3.10-197)	0.012
SII, on hospitalization	1834.97 (254.19-12,962.43)	1953.0 (254.19-11,059.84)	1064 (352.87-12,962.43)	0.016
SII, before IVIG treatment	4,166.94 (657.69-22,356.46)	5,086.86 (657.69-22,356.46)	3,753.21 (1,354.69-13,441.37)	0.013
NLR, on hospitalization	9.19 (1.86-42.21)	9.28 (1.93-42.21)	7.24 (1.86-30.72)	0.075
NLR, before IVIG treatment	23.21 (2.33-126.31)	26.08 (2.33-126.31)	16.15 (5.80-27.66)	0.001

353 F: Female, IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red
354 cell distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase,
355 AST: Aspartate Aminotransferase, LDH: Lactate dehydrogenase, Ig: Immunoglobulin,
356 CRP: C-reactive protein, SII: Systemic inflammatory index, NLR: Neutrophil
357 lymphocyte ratio

358

Table 2: Univariate Cox regression analyses demonstrating the relationship between baseline characteristics and Sars-CoV-2

Variable	Univariate Analysis	
	HR (95% CI)	P value
Day of stay in inpatient service	0.951 (0.906 – 0.998)	0.043
Intubation	16.370 (4.353-61.565)	0.001
Intensive care	0.923 (0.316-0.270)	0.884
Pulse steroid therapy	0.910 (0.525 – 1.580)	0.738
Tocilizumab treatment	1.436 (0.794 – 2.552)	0.236
Duration of IVIG treatment, day	1.419 (0.966 – 2.083)	0.074
IgG, on hospitalization	1.234 (0.964 – 1.581)	0.096
WBC, before IVIG treatment	1.000 (1.000 – 1.000)	0.418
Neutrophil count, on hospitalization	1.000 (1.000 – 1.000)	0.946
Platelet count, on hospitalization	1.001 (0.998 – 1.004)	0.405
Eosinophil count, IVIG öncesi	0.994 (0.983 – 1.006)	0.307
FBG, on hospitalization	1.002 (0.998 – 1.005)	0.299
FBG, before IVIG treatment	1.002 (0.999 – 1.006)	0.192
Urea, before IVIG treatment	1.011 (1.003 – 1.018)	0.004
LDH, on hospitalization	1.000 (0.999 – 1.000)	0.722
LDH, before IVIG treatment	1.000 (0.999 – 1.001)	0.695
IgA, on hospitalization	1.025 (0.740 – 1.421)	0.880
CRP, on hospitalization	1.002 (0.999 – 1.005)	0.111
CRP, before IVIG treatment	1.001 (0.998 – 1.005)	0.364

SII, on hospitalization	1.000 (1.000 – 1.000)	0.746
SII, before IVIG treatment	1.000 (1.000 – 1.000)	0.314
NLR, on hospitalization	1.002 (0.979 – 1.025)	0.884
NLR, before IVIG treatment	1.004 (0.994 – 1.014)	0.414

361 Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, F: Female,
 362 IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red cell
 363 distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase, AST:
 364 Aspartate Aminotransferase, FBG: Fasting blood glucose, LDH: Lactate
 365 dehydrogenase, Ig: Immunoglobulin, CRP: C-reactive protein, SII: Systemic
 366 inflammatory index, NLR: Neutrophil lymphocyte ratio

367

368

369

370 **Table 3:** Multivariate Cox regression analyses demonstrating the relationship between
 371 baseline characteristics and Sars-CoV-2

Variables	Multivariate Analysis	
	HR (95% CI)	P value
Intubation	0.389 (0.218 – 0.693)	0.001
Day of stay in inpatient service	0.968 (0.915 – 1.024)	0.256
Duration of IVIG treatment, day	0.833 (0.652 – 1.065)	0.145
Urea, before IVIG treatment	1.009 (1.002 – 1.017)	0.009

372 Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, IVIG:
 373 Intravenous immunoglobulin

374

Table 4: Sensitivity and specificity of urea level before IVIG treatment

Risk factor	AUC (95%)	Cut-off	p	Sensitivity	Specificity
Urea, before IVIG treatment	0.647 (0.518 - 0.776)	60	0.029	46.2	35.5

AUC: Area under the curve, IVIG: Intravenous immunoglobulin

Figure 1: Sensitivity and specificity of urea level before IVIG treatment

